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THE UNCOUPLING OF DIAGNOSIS AND IMMEDIATE
TREATMENT IN VERY LOW AND LOW RISK PROSTATE
CANCER: A NATIONAL PERSPECTIVERichard Matulewicz*, John Oliver DeLancey, Anuj Desai, AdamWeiner,
Edward Schaeffer, Chicago, IL
INTRODUCTION AND OBJECTIVES: A critical means of
reducing the morbidity associated with screening for prostate cancer
(CaP) is uncoupling diagnosis from treatment. In some men, treatment
risks may outweigh beneﬁts. We sought to understand the current
treatment landscape of men with very low or low risk (VLoLR) CaP and
to determine factors associated with receiving treatment in a contem-
porary national cohort.
METHODS: Using the National Cancer Database for the years
2010-2013, men with CaP were categorized into risk groups using
NCCN criteria by PSA, Gleason score, cT stage, and number of positive
cores. In men with VLoLR CaP, radical prostatectomy (RP), radio-
therapy (RT), or androgen deprivation therapy (ADT) within 1 year was
considered immediate treatment. Men managed with active surveillance
(AS), watchful waiting (WW), or no treatment (NoTx) were also
analyzed. Treatment patterns by age, comorbidities, and diagnosis year
were assessed. Logistic regression modeling was used to determine
factors associated with higher likelihood of receiving any treatment.
RESULTS: Of 448,810 men diagnosed with CaP, 46,290
(11.9%) had very low risk and 60,122 (15.5%) had low risk CaP. In this
combined VLoLR Cap cohort, overall median age was 62 with 34.6% of
men being older than 65. Overall, 74.8% of men with VLoLR CaP
received primary treatment within 1 year of diagnosis. Primary treatment
rates declined over time while management with AS/WW/NoTx
increased (Figure 1). In men >65 with VLoLR CaP, 28.9% had RP,
35.9% got RT, and 19.2% had AS/WW/NoTx. In men >75, only 5.3%
received RP, 39.9% got RT, and 25.4% had AS/WW/NoTx. Age >65
(OR 0.55 95% CI 0.53-0.57), being treated at an academic center (OR
0.68, 95% CI 0.66-0.71), and progressive years after 2010 were
associated with lower odds of treatment (Table 1).
CONCLUSIONS: Signiﬁcant numbers of men with VLoLR CaP
underwent primary treatment during 2010-2013, including older men, in
whom there is no established beneﬁt to treatment. However, a trend
toward more conservative management is apparent.Source of Funding: noneMP14-02
THE NATURAL HISTORY OF MEN ON ACTIVE
SURVEILLANCE WITH LOW-RISK PROSTATE CANCER
AT A SAFETY-NET, COUNTY HOSPITALE. Charles Osterberg, Austin, TX; Nynikka Palmer, Catherine Harris,
Gregory Murphy, Sarah Blaschko, Carissa Chu*, Matthew Cooperberg,
Peter Carroll, Benjamin Breyer, San Francisco, CA
INTRODUCTION AND OBJECTIVES: Health care delivery to
vulnerableanduninsuredpatients ischallengingdue tosocial andeconomic
barriers. For menwith low-risk prostate cancer (PCa) on active surveillance
(AS), patient compliance, follow up, and access to care are essential for
favorable cancer outcomes. Our primary objective is to characterize
demographic, disease and cancer outcomes of men on AS at a safety-net
hospital and characterize those who were loss to follow-up (LTFU).
METHODS: From January 2004 to November 2014, 104 men at
Zuckerberg San Francisco General (ZSFG) with low-risk PCa were
followed with AS. Criteria for AS has evolved over time; however, patients
with diagnostic PSA 10ng/mL or less, clinical stage T1/2, biopsy Gleason
grade 3+3 or 3+4, 33% or fewer positive cores and 50% or less tumor in
any single core were eligible for AS. Men were longitudinally followed with
a PSA and/or DRE every 3-6 months and repeat prostate biopsy every
1-2 years. Clinical staging and grading were based on a physical exam
and at least a 12-core biopsy respectively. LTFU was deﬁned as failure to
contact patients with three phone calls or any urology visit recorded within
18 months from a prior visit or biopsy. A secondary chart review was
performed with EPIC Systems CareEverywhere which allows access to
non-ZSFG institutions to conﬁrm patients were truly LTFU.
RESULTS: Among the 104 men on AS at ZSFG, the median
age at diagnosis of PCa was 61.5 years (range: 44-81). The median
follow-up time period was 29 months (0-186 months) during which 18
men were LTFU and 48 remained on surveillance. Men who remained
on AS underwent a median of 7 (1-21) serum PSA measurements and
an average of 2 prostate biopsies (1-5). In total, 22 (20.6%) men had
deﬁnitive treatment with the median time from diagnosis to active
treatment being 26 (2-87) months. Radiation therapy was more com-
mon that radical prostatectomy (12.5% versus 7.7%). There was one
prostate cancer-related death and three non-cancer deaths. Kaplan-
Meir curve analysis demonstrates that initial adherence to AS is poor;
however as time progresses, adherence increases as those patients
committed to early surveillance continue with follow-up.
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among a vulnerable population receiving care in a safety-net hospital,
as rates of LTFU were high. Our ﬁndings suggest the need for an AS
program to improve adherence and follow-up among vulnerable and
underserved populations.
Source of Funding: Alaﬁ FoundationMP14-03
HIGHER CHOLESTEROL IS LINKED WITH INCREASED
RISK OF HIGH-GRADE PROSTATE CANCER: RESULTS
FROM THE REDUCE STUDYJuzar Jamnagerwalla*, Los Angeles, CA; Lauren E. Howard, Durham,
NC; Adriana C. Vidal, Los Angeles, CA; Daniel M. Moreira, Rochester,
MN; Ramiro Castro-Santamaria, King of Prussia, PA;
Gerald L. Andriole, St. Louis, MO; Stephen J. Freedland,
Los Angeles, CA
INTRODUCTION AND OBJECTIVES: Given the prevalence of
prostate cancer (PC) and hypercholesterolemia, multiple studies have
examined the link between these two conditions with mixed results.
These ﬁndings may be inﬂuenced by studies showing a correlation
between higher cholesterol and higher PSA, introducing a bias that may
impact the rate of prostate biopsy and cancer detection thereby making
high cholesterol appear to be correlated with PC risk. We tested the
association between serum lipids and PC in a post-hoc analysis of the
REDUCE study, in which subjects underwent study mandated biopsies
regardless of PSA, mitigating any bias due to PSA.
METHODS: REDUCEwas a 4 year multi-center study testing the
effect of dutasteride on PC risk in men with a PSA of 2.5-10.0 ng/mL and a
negative pre-enrollment biopsy. As part of the study protocol subjects were
required to undergo study-mandated biopsies. The associations between
baseline serum cholesterol, low-density lipoprotein cholesterol (LDL) and
high-density lipoprotein cholesterol (HDL) with overall PC risk and disease
grade (Gleason 2-6 vs. 7-10) at the 2-year biopsy was examined with lo-
gistic and multinomial logistic regression, adjusted for baseline covariates.
Continuous lipid levels were presented in 10 mg/dL increments to help
interpret hazard ratios. We excluded men taking statins.
RESULTS: 4,904 subjects not taking statins were included.
Elevated serum cholesterol was associatedwith a higher risk of high-grade
PC diagnosis on multivariable analysis (OR 1.23, p¼0.008), though no
association was seen between overall or low-gradePC risk (p>0.137). No
association was seen between serum LDL and overall risk of PC or low- or
high-grade disease (p >0.138). In contrast, elevated serum HDL was
associatedwithahigher riskofoverallPCrisk (OR1.34,p¼0.028)andhigh-
grade PC risk (OR 1.74, p¼0.013) on multivariable analysis.
CONCLUSIONS: In post hoc analysis of REDUCE, both
elevated cholesterol and elevated HDL were associated with increased
high-grade PC risk. These data support the hypothesis that high
cholesterol is linked with aggressive PC. Given recent data questioning
the role of HDL as a cardioprotective factor (Ko et al, J Am College of
Cardiology, 2016) and a meta-analysis showing drugs that increase
HDL do not reduce cardiovascular risk (Keene et al, BMJ 2014), further
study is needed to better understand the link between high HDL and
increased PC risk.
Source of Funding: Supported by GlaxoSmithKline and NIH
1K24CA160653MP14-04
CARDIOVASCULAR DISEASE CHARACTERISTICS OF
NEWLY DIAGNOSED PROSTATE CANCER PATIENTS:
FINDINGS FROM THE PILOT PHASE OF RADICAL PC: A
PROSPECTIVE STUDY OF CARDIOVASCULAR DISEASE IN
MEN WITH PROSTATE CANCERJehonathan Pinthus*, Hamilton, Canada; Laurence Klotz, Toronto,
Canada; Himu Lukka, Philip J Devereaux, Kayla Pohl, Hamilton,Canada; Idan Roifman, Toronto, Canada; Vincent Fradet, Quebec City,
Canada; Robert Siemens, Kingston, Canada; Tamara Wallington,
Brampton, Canada; Shayegan Bobby, Edward Matsumoto,
Tom Corbett, Wilhelmina Duivenvoorden, Mahshid Dehghan, Hamilton,
Canada; Marina Mourtzakis, Waterloo, Canada; Darryl P. Leong,
Hamilton, Canada
INTRODUCTION AND OBJECTIVES: Administrative registries
suggest that cardiovascular (CV) disease develops frequently in men
with prostate cancer (PC). Known CV risk factors, such as hyperten-
sion, dyslipidemia, and obesity may account for some of the risk,
however PC-speciﬁc factors, including androgen deprivation therapy
(ADT) may also play a role. The goals of RADICAL PC are to identify
the incidence and major determinants of CV disease, and to evaluate
whether systematic CV risk factor modiﬁcation reduces adverse CV
events in men with PC. We report the ﬁndings for the pilot phase of this
study.
METHODS: RADICAL PC recruits consecutive men with a new
diagnosis of PC or commencing ADT for the 1st time. Those who do not
see a cardiologist annually are randomized in an open manner to
receive a CV risk factor intervention (aspirin, statin, blood pressure-
lowering to a target systolic of 130mmHg, and standardized exercise
and dietary counseling). Those not eligible for randomization are
followed to provide a representative sample. At least 6000 men will be
recruited and followed for an average of 3 years. Renal function, lipids,
and HbA1c will be measured serially. The primary endpoint is the
composite of CV death, myocardial infarction, stroke, heart failure, or
arterial revascularization. Fisher’s exact test and ANOVA test were
used for categorical and normally distributed continuous variables
comparisons respectively.
RESULTS: The characteristics of the ﬁrst 421 participants, from
3 Canadian sites, are presented. Of these, 334 were newly diagnosed
and 87 were receiving ADT for the 1st time, 25 had metastatic disease
and 62 were undergoing radiotherapy. Of all participants, 56% have
been randomized, and the remainders are undergoing passive follow
up. 41% of the patients had hypertension and of the 246 participants
with no known hypertension, additional 31% had blood pressure in the
hypertensive range. 17% of the patients are diabetic, 55% are current or
previous smokers and 81% are overweight (45%) or obese (36%). A
third of the patients are on statins and a third take ASA. Patients who
are commencing on ADT are older (67+/-8.4 vs. 71+/-8.3 years
p<0.0001) and have higher prevalence of preexisting coronary artery
disease (11% vs. 20% p¼0.003) compared to those who have no
indication for ADT.
CONCLUSIONS: Pre-established cardiovascular disease and
its risk factors are very common in newly diagnosed prostate cancer
patients. The baseline characteristics of patients who are planned to
initiate ADT may place them in a higher CVS risk compared to the
general PC patient population.
Source of Funding: PROSTATE CANCER CANADA
Hamilton Health Sciences RFA strategic initiativeMP14-05
THE ASSOCIATION OF AGE WITH PERIOPERATIVE
MORBIDITY AND MORTALITY AMONG PATIENTS
UNDERGOING RADICAL PROSTATECTOMYJorge Pereira*, Gyan Pareek, Dragan Golijanin, Joseph Renzulli,
Boris Gershman, Providence, RI
INTRODUCTION AND OBJECTIVES: Older age has been
considered a relative contraindication to radical prostatectomy (RP) in
men who are otherwise candidates for deﬁnitive local therapy for
prostate cancer. However, there are limited data regarding the associ-
ation of age with perioperative outcomes following RP, which is
particularly relevant given increased life expectancy in the United
States. We therefore examined the association of age with periopera-
tive outcomes among men undergoing RP to more fully inform risk-
assessment and management.
